Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function

Peginterferon beta-1a was efficacious in a Phase 3 relapsing multiple sclerosis trial, and its safety profile was consistent with other beta interferons. This study evaluated the impact of renal impairment on the pharmacokinetics and pharmacodynamics (neopterin elevation; a biomarker of pharmacologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiao, Seddighzadeh, Ali, Stecher, Scott, Zhu, Ying, Goyal, Jaya, Matson, Mark, Marbury, Thomas, Smith, William, Nestorov, Ivan, Hung, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303928/
https://www.ncbi.nlm.nih.gov/pubmed/25187030
http://dx.doi.org/10.1002/jcph.390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303928/
https://www.ncbi.nlm.nih.gov/pubmed/25187030
http://dx.doi.org/10.1002/jcph.390

Ejemplares similares